



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70702

Title: Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06125275

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Algeria

Author's Country/Territory: China

Manuscript submission date: 2021-08-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-16 18:25

Reviewer performed review: 2021-08-16 19:26

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Like stromal tumors, the apparition of drug resistance to TKI (thyrosine kinase inhibitor) constitute a big challenge for physicians. This case report caught our attention to the possibility of this mutation to another cellular type (adenocarcinoma to SCLC) which can modify the prognosis. The manuscript is clear easy to read. His english is well understood. the following points merit consideration: You must add in the discussion if you can more references about this cancerous transformation that have been well evolved after 3rd generation TKI introduction. You cannot generalize from one case that the 3rd line TKI had apported an objective and good results because you've had associated carboplatine and etoposide. this encouraging result should be taken with caution. You had submitted the patient to 4 series of biopsy. In my opinion it's to aggressive. You must develop the dna method of circulating cells to detect any tumor mutation.